Colorectal Cancer
New data show Erbitux offers hope for many metastatic patients
Published in Cancer Weekly, June 24th, 2003
Merck, KGaA, of Darmstadt, Germany, said that data from its European colorectal cancer (BOND) study demonstrate that Erbitux (cetuximab), when used in combination with irinotecan, represents a significant advance in the treatment of patients with metastatic colorectal cancer, slowing progression of the disease by more than 4 months and shrinking tumors by 50% or more in 22.9% of patients.
Half of all patients saw their disease stabilize or improve.
Median survival time for the advanced-stage patients treated with the combination therapy was 8.6 months, with approximately a third of the 329 patients in the study alive after 1 year.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-06-24)
More Articles from Cancer Weekly
- Laryngeal Cancer
Combination treatment saves voice - Stomach Cancer
New chemotherapy combination lengthens survival in late-stage disease - Brain Cancer
Glioblastoma and meningioma have differential vascular networks - Breast Cancer
Phase II study shows new p53 drug therapy can enhance presurgical chemotherapy - Hepatocellular Carcinoma
E-cadherin is a marker for the risk of liver cancer recurrence after resection - Neuroblastoma
'Disappearing' tumor study could lead to new cancer treatments - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
